Skip to main content
Top
Published in: Calcified Tissue International 5/2013

01-05-2013 | Original Research

Further Analysis of the Crouzon Mouse: Effects of the FGFR2C342Y Mutation Are Cranial Bone–Dependent

Authors: Jin Liu, Hwa Kyung Nam, Estee Wang, Nan E. Hatch

Published in: Calcified Tissue International | Issue 5/2013

Login to get access

Abstract

Crouzon syndrome is a debilitating congenital disorder involving abnormal craniofacial skeletal development caused by mutations in fibroblast growth factor receptor-2 (FGFR2). Phenotypic expression in humans exhibits an autosomal dominant pattern that commonly involves premature fusion of the coronal suture (craniosynostosis) and severe midface hypoplasia. To further investigate the biologic mechanisms by which the Crouzon syndrome–associated FGFR2C342Y mutation leads to abnormal craniofacial skeletal development, we created congenic BALB/c FGFR2C342Y/+ mice. Here, we show that BALB/c FGFR2C342Y/+ mice have a consistent craniofacial phenotype including partial fusion of the coronal and lambdoid sutures, intersphenoidal synchondrosis, and multiple facial bones, with minimal fusion of other craniofacial sutures. This phenotype is similar to the classic and less severe form of Crouzon syndrome that involves significant midface hypoplasia with limited craniosynostosis. Linear and morphometric analyses demonstrate that FGFR2C342Y/+ mice on the BALB/c genetic background differ significantly in form and shape from their wild-type littermates and that in this genetic background the FGFR2C342Y mutation preferentially affects some craniofacial bones and sutures over others. Analysis of cranial bone cells indicates that the FGFR2C342Y mutation promotes aberrant osteoblast differentiation and increased apoptosis that is more severe in frontal than parietal bone cells. Additionally, FGFR2C342Y/+ frontal, but not parietal, bones exhibit significantly diminished bone volume and density compared to wild-type mice. These results confirm that FGFR2-associated craniosynostosis occurs in association with diminished cranial bone tissue and may provide a potential biologic explanation for the clinical finding of phenotype consistency that exists between many Crouzon syndrome patients.
Literature
1.
go back to reference Renier D, Lajeunie E, Arnaud E, Marchac D (2000) Management of craniosynostoses. Childs Nerv Syst 16(10–11):645–658PubMedCrossRef Renier D, Lajeunie E, Arnaud E, Marchac D (2000) Management of craniosynostoses. Childs Nerv Syst 16(10–11):645–658PubMedCrossRef
2.
go back to reference Seruya M, Oh AK, Boyajian MJ, Posnick JC, Keating RF (2011) Treatment for delayed presentation of sagittal synostosis: challenges pertaining to occult intracranial hypertension. J Neurosurg Pediatr 8(1):40–48PubMedCrossRef Seruya M, Oh AK, Boyajian MJ, Posnick JC, Keating RF (2011) Treatment for delayed presentation of sagittal synostosis: challenges pertaining to occult intracranial hypertension. J Neurosurg Pediatr 8(1):40–48PubMedCrossRef
3.
go back to reference Morriss-Kay GM, Wilkie AO (2005) Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. J Anat 207(5):637–653PubMedCrossRef Morriss-Kay GM, Wilkie AO (2005) Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. J Anat 207(5):637–653PubMedCrossRef
4.
go back to reference Kreiborg S (1981) Craniofacial growth in plagiocephaly and Crouzon syndrome. Scand J Plast Reconstr Surg 15(3):187–197PubMedCrossRef Kreiborg S (1981) Craniofacial growth in plagiocephaly and Crouzon syndrome. Scand J Plast Reconstr Surg 15(3):187–197PubMedCrossRef
5.
go back to reference Cohen MM Jr (1993) Sutural biology and the correlates of craniosynostosis. Am J Med Genet 47:581–616PubMedCrossRef Cohen MM Jr (1993) Sutural biology and the correlates of craniosynostosis. Am J Med Genet 47:581–616PubMedCrossRef
6.
go back to reference Okajima K, Robinson LK, Hart MA, Abuelo DN, Cowan LS, Hasegawa T, Maumenee IH, Jabs EW (1999) Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. Am J Med Genet 85(2):160–170PubMedCrossRef Okajima K, Robinson LK, Hart MA, Abuelo DN, Cowan LS, Hasegawa T, Maumenee IH, Jabs EW (1999) Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. Am J Med Genet 85(2):160–170PubMedCrossRef
7.
go back to reference Stavrou P, Sgouros S, Willshaw HE, Goldin JH, Hockley AD, Wake MJ (1997) Visual failure caused by raised intracranial pressure in craniosynostosis. Childs Nerv Syst 13(2):64–67PubMedCrossRef Stavrou P, Sgouros S, Willshaw HE, Goldin JH, Hockley AD, Wake MJ (1997) Visual failure caused by raised intracranial pressure in craniosynostosis. Childs Nerv Syst 13(2):64–67PubMedCrossRef
8.
go back to reference Abe H, Ikota T, Akino M, Kitami K, Tsuru M (1985) Functional prognosis of surgical treatment of craniosynostosis. Childs Nerv Syst 1(1):53–61PubMedCrossRef Abe H, Ikota T, Akino M, Kitami K, Tsuru M (1985) Functional prognosis of surgical treatment of craniosynostosis. Childs Nerv Syst 1(1):53–61PubMedCrossRef
9.
go back to reference Shah PS, Siriwardena K, Taylor G, Steele L, Ray P, Blaser S, Chitayat D (2006) Sudden infant death in a patient with FGFR3 P250R mutation. Am J Med Genet A 140(24):2794–2796PubMed Shah PS, Siriwardena K, Taylor G, Steele L, Ray P, Blaser S, Chitayat D (2006) Sudden infant death in a patient with FGFR3 P250R mutation. Am J Med Genet A 140(24):2794–2796PubMed
10.
go back to reference Rasmussen SA, Yazdy MM, Frías JL, Honein MA (2008) Priorities for public health research on craniosynostosis: summary and recommendations from a Centers for Disease Control and Prevention-sponsored meeting. Am J Med Genet A 146A(2):149–158PubMedCrossRef Rasmussen SA, Yazdy MM, Frías JL, Honein MA (2008) Priorities for public health research on craniosynostosis: summary and recommendations from a Centers for Disease Control and Prevention-sponsored meeting. Am J Med Genet A 146A(2):149–158PubMedCrossRef
11.
go back to reference Cohen MM Jr, Kreiborg S (1992) Upper and lower airway compromise in the Apert syndrome. Am J Med Genet 44(1):90–93PubMedCrossRef Cohen MM Jr, Kreiborg S (1992) Upper and lower airway compromise in the Apert syndrome. Am J Med Genet 44(1):90–93PubMedCrossRef
12.
go back to reference Cunningham ML, Seto ML, Ratisoontorn C, Heike CL, Hing AV (2007) Syndromic craniosynostosis: from history to hydrogen bonds. Orthod Craniofac Res 10(2):67–81PubMedCrossRef Cunningham ML, Seto ML, Ratisoontorn C, Heike CL, Hing AV (2007) Syndromic craniosynostosis: from history to hydrogen bonds. Orthod Craniofac Res 10(2):67–81PubMedCrossRef
13.
go back to reference Flapper WJ, Anderson PJ, Roberts RM, David DJ (2009) Intellectual outcomes following protocol management in Crouzon, Pfeiffer, and Muenke syndromes. J Craniofac Surg 20(4):1252–1255PubMedCrossRef Flapper WJ, Anderson PJ, Roberts RM, David DJ (2009) Intellectual outcomes following protocol management in Crouzon, Pfeiffer, and Muenke syndromes. J Craniofac Surg 20(4):1252–1255PubMedCrossRef
14.
go back to reference Baird LC, Gonda D, Cohen SR, Evers LH, Lefloch N, Levy ML, Meltzer HS (2011) Craniofacial reconstruction as a treatment for elevated intracranial pressure. Childs Nerv Syst 28(3):411–418PubMedCrossRef Baird LC, Gonda D, Cohen SR, Evers LH, Lefloch N, Levy ML, Meltzer HS (2011) Craniofacial reconstruction as a treatment for elevated intracranial pressure. Childs Nerv Syst 28(3):411–418PubMedCrossRef
15.
go back to reference Boyadjiev SA, International Craniosynostosis Consortium (2007) Genetic analysis of non-syndromic craniosynostosis. Orthod Craniofac Res 10(3):129–137PubMedCrossRef Boyadjiev SA, International Craniosynostosis Consortium (2007) Genetic analysis of non-syndromic craniosynostosis. Orthod Craniofac Res 10(3):129–137PubMedCrossRef
16.
go back to reference Wilkie AO, Byren JC, Hurst JA, Jayamohan J, Johnson D, Knight SJ, Lester T, Richards PG, Twigg SR, Wall SA (2010) Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics 126(2):e391–e400PubMedCrossRef Wilkie AO, Byren JC, Hurst JA, Jayamohan J, Johnson D, Knight SJ, Lester T, Richards PG, Twigg SR, Wall SA (2010) Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics 126(2):e391–e400PubMedCrossRef
17.
go back to reference Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8:98–103PubMedCrossRef Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8:98–103PubMedCrossRef
18.
go back to reference Schell U, Hehr A, Feldman GJ, Robin NH, Zackai EH, de Die-Smulders C, Viskochil DH, Stewart JM, Wolff G, Ohashi H et al (1995) Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet 4:323–328PubMedCrossRef Schell U, Hehr A, Feldman GJ, Robin NH, Zackai EH, de Die-Smulders C, Viskochil DH, Stewart JM, Wolff G, Ohashi H et al (1995) Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet 4:323–328PubMedCrossRef
19.
go back to reference Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P et al (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165–172PubMedCrossRef Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P et al (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165–172PubMedCrossRef
20.
go back to reference Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13:69–78PubMedCrossRef Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13:69–78PubMedCrossRef
21.
go back to reference Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101:12555–12560PubMedCrossRef Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101:12555–12560PubMedCrossRef
22.
go back to reference Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, Yang J, Jin M, Deng C, Chen L (2008) A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42:631–643PubMedCrossRef Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, Yang J, Jin M, Deng C, Chen L (2008) A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42:631–643PubMedCrossRef
23.
go back to reference Cohen MM Jr, Kreiborg S (1992) Birth prevalence studies of the Crouzon syndrome: comparison of direct and indirect methods. Clin Genet 41(1):12–15PubMedCrossRef Cohen MM Jr, Kreiborg S (1992) Birth prevalence studies of the Crouzon syndrome: comparison of direct and indirect methods. Clin Genet 41(1):12–15PubMedCrossRef
25.
go back to reference Perlyn CA, DeLeon VB, Babbs C, Govier D, Burell L, Darvann T, Kreiborg S, Morriss-Kay G (2006) The craniofacial phenotype of the Crouzon mouse: analysis of a model for syndromic craniosynostosis using three-dimensional microCT. Cleft Palate Craniofac J 43(6):740–748PubMedCrossRef Perlyn CA, DeLeon VB, Babbs C, Govier D, Burell L, Darvann T, Kreiborg S, Morriss-Kay G (2006) The craniofacial phenotype of the Crouzon mouse: analysis of a model for syndromic craniosynostosis using three-dimensional microCT. Cleft Palate Craniofac J 43(6):740–748PubMedCrossRef
26.
go back to reference Flippen JH Jr (1950) Cranio-facial dysostosis of Crouzon; report of a case in which the malformation occurred in four generations. Pediatrics 5(1):90–96PubMed Flippen JH Jr (1950) Cranio-facial dysostosis of Crouzon; report of a case in which the malformation occurred in four generations. Pediatrics 5(1):90–96PubMed
27.
go back to reference Holmes G, Rothschild G, Roy UB, Deng C, Mansukhani A, Basilico C (2009) Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328:273–284PubMedCrossRef Holmes G, Rothschild G, Roy UB, Deng C, Mansukhani A, Basilico C (2009) Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328:273–284PubMedCrossRef
28.
go back to reference Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9:2001–2008PubMedCrossRef Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9:2001–2008PubMedCrossRef
29.
go back to reference Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D, Marie PJ (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 101:1310–1317PubMed Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D, Marie PJ (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 101:1310–1317PubMed
30.
go back to reference Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliaccio S (1999) Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154:1465–1477PubMedCrossRef Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliaccio S (1999) Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154:1465–1477PubMedCrossRef
31.
go back to reference Mansukhani A, Bellosta P, Sahni M, Basilico C (2000) Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Bone Miner Res 149:1297–1308 Mansukhani A, Bellosta P, Sahni M, Basilico C (2000) Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Bone Miner Res 149:1297–1308
32.
go back to reference Chen L, Li D, Li C, Engel A, Deng CX (2003) A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33:169–171PubMedCrossRef Chen L, Li D, Li C, Engel A, Deng CX (2003) A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33:169–171PubMedCrossRef
33.
go back to reference Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, Jabs EW (2010) Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Dev Biol 10:22PubMedCrossRef Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, Jabs EW (2010) Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Dev Biol 10:22PubMedCrossRef
34.
go back to reference Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM, Wilkie AO (2009) Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dyn 238(2):331–342PubMedCrossRef Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM, Wilkie AO (2009) Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dyn 238(2):331–342PubMedCrossRef
35.
go back to reference Richtsmeier JT, Baxter LL, Reeves RH (2000) Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217(2):137–145PubMedCrossRef Richtsmeier JT, Baxter LL, Reeves RH (2000) Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217(2):137–145PubMedCrossRef
36.
go back to reference Lele S, Richtsmeier JT (2001) An invariant approach to statistical analysis of shapes. Chapman & Hall/CRC, Boca RatonCrossRef Lele S, Richtsmeier JT (2001) An invariant approach to statistical analysis of shapes. Chapman & Hall/CRC, Boca RatonCrossRef
37.
go back to reference Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486PubMedCrossRef Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486PubMedCrossRef
38.
go back to reference Hatch N, Li Y, Franceschi RT (2009) FGF2 stimulated expression of the pyrophosphate generating enzyme, PC-1, is mediated by Runx2. J Bone Miner Res 24(4):652–662PubMedCrossRef Hatch N, Li Y, Franceschi RT (2009) FGF2 stimulated expression of the pyrophosphate generating enzyme, PC-1, is mediated by Runx2. J Bone Miner Res 24(4):652–662PubMedCrossRef
39.
go back to reference McCarthy TL, Centrella M, Canalis E (1988) Further biochemical and molecular characterization of primary rat parietal bone cell cultures. J Bone Miner Res 3(4):401–408PubMedCrossRef McCarthy TL, Centrella M, Canalis E (1988) Further biochemical and molecular characterization of primary rat parietal bone cell cultures. J Bone Miner Res 3(4):401–408PubMedCrossRef
40.
go back to reference Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9(3):389–394PubMedCrossRef Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9(3):389–394PubMedCrossRef
41.
go back to reference Ducy P, Karsenty G (1995) Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 15(4):1858–1869PubMed Ducy P, Karsenty G (1995) Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 15(4):1858–1869PubMed
42.
go back to reference Martínez-Abadías N, Heuzé Y, Wang Y, Jabs EW, Aldridge K, Richtsmeier JT (2011) FGF/FGFR signaling coordinates skull development by modulating magnitude of morphological integration: evidence from Apert syndrome mouse models. PLoS One 6(10):e26425PubMedCrossRef Martínez-Abadías N, Heuzé Y, Wang Y, Jabs EW, Aldridge K, Richtsmeier JT (2011) FGF/FGFR signaling coordinates skull development by modulating magnitude of morphological integration: evidence from Apert syndrome mouse models. PLoS One 6(10):e26425PubMedCrossRef
43.
go back to reference Holmes G, Basilico C (2012) Mesodermal expression of Fgfr2S252 W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome. Dev Biol 368(2):283–293PubMedCrossRef Holmes G, Basilico C (2012) Mesodermal expression of Fgfr2S252 W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome. Dev Biol 368(2):283–293PubMedCrossRef
44.
go back to reference Li S, Quarto N, Longaker MT (2010) Activation of FGF signaling mediates proliferative and osteogenic differences between neural crest derived frontal and mesoderm parietal derived bone. PLoS One 5(11):e14033PubMedCrossRef Li S, Quarto N, Longaker MT (2010) Activation of FGF signaling mediates proliferative and osteogenic differences between neural crest derived frontal and mesoderm parietal derived bone. PLoS One 5(11):e14033PubMedCrossRef
45.
go back to reference Behr B, Panetta NJ, Longaker MT, Quarto N (2010) Different endogenous threshold levels of fibroblast growth factor ligands determine the healing potential of frontal and parietal bones. Bone 47(2):281–294PubMedCrossRef Behr B, Panetta NJ, Longaker MT, Quarto N (2010) Different endogenous threshold levels of fibroblast growth factor ligands determine the healing potential of frontal and parietal bones. Bone 47(2):281–294PubMedCrossRef
46.
go back to reference Quarto N, Behr B, Li S, Longaker MT (2009) Differential FGF ligands and FGF receptors expression pattern in frontal and parietal calvarial bones. Cells Tissues Organs 190(3):158–169PubMedCrossRef Quarto N, Behr B, Li S, Longaker MT (2009) Differential FGF ligands and FGF receptors expression pattern in frontal and parietal calvarial bones. Cells Tissues Organs 190(3):158–169PubMedCrossRef
47.
go back to reference Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K, Morriss-Kay GM (1997) Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124:3375–3384PubMed Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K, Morriss-Kay GM (1997) Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124:3375–3384PubMed
48.
go back to reference Iseki S, Wilkie AO, Morriss-Kay GM (1999) Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126:5611–5620PubMed Iseki S, Wilkie AO, Morriss-Kay GM (1999) Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126:5611–5620PubMed
49.
go back to reference Lemonnier J, Haÿ E, Delannoy P, Fromigué O, Lomri A, Modrowski D, Marie PJ (2001) Increased osteoblast apoptosis in Apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol 158(5):1833–1842PubMedCrossRef Lemonnier J, Haÿ E, Delannoy P, Fromigué O, Lomri A, Modrowski D, Marie PJ (2001) Increased osteoblast apoptosis in Apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol 158(5):1833–1842PubMedCrossRef
Metadata
Title
Further Analysis of the Crouzon Mouse: Effects of the FGFR2C342Y Mutation Are Cranial Bone–Dependent
Authors
Jin Liu
Hwa Kyung Nam
Estee Wang
Nan E. Hatch
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 5/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9701-2

Other articles of this Issue 5/2013

Calcified Tissue International 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.